HAPLOTYPE AND PHYLOGENETIC ANALYSES SUGGEST THAT ONE EUROPEAN-SPECIFIC MTDNA BACKGROUND PLAYS A ROLE IN THE EXPRESSION OF LEBER HEREDITARY OPTIC NEUROPATHY BY INCREASING THE PENETRANCE OF THE PRIMARY MUTATION-11778 AND MUTATION-14484
A. Torroni et al., HAPLOTYPE AND PHYLOGENETIC ANALYSES SUGGEST THAT ONE EUROPEAN-SPECIFIC MTDNA BACKGROUND PLAYS A ROLE IN THE EXPRESSION OF LEBER HEREDITARY OPTIC NEUROPATHY BY INCREASING THE PENETRANCE OF THE PRIMARY MUTATION-11778 AND MUTATION-14484, American journal of human genetics, 60(5), 1997, pp. 1107-1121
mtDNAs from 37 Italian subjects affected by Leber hereditary optic neu
ropathy (LHON) (28 were 11778 positive, 7 were 3460 positive, and 2 we
re 14484 positive) and from 99 Italian controls were screened for most
of the mutations that currently are associated with LHON. High-resolu
tion restriction-endonuclease analysis also was performed on all subje
cts, in order to define the phylogenetic relationships between the mtD
NA haplotypes and the LHON mutations observed in patients and in contr
ols. This analysis shows that the putative secondary/intermediate LHON
mutations 4216, 4917, 13708, 15257, and 15812 are ancient polymorphis
ms, are associated in specific combinations, and define two common Cau
casoid-specific haplotype groupings (haplogroups J and T). On the cont
rary, the same analysis shows that the primary mutations 11778, 3460,
and 14484 are recent and are due to multiple mutational events. Howeve
r, phylogenetic analysis also reveals a different evolutionary pattern
for the three primary mutations. The 3460 mutations are distributed r
andomly along the phylogenetic trees, without any preferential associa
tion with the nine haplogroups (H, I, J, K, T, U, V, W, and X) that ch
aracterize European populations, whereas the 11778 and 14484 mutations
show a strong preferential association with haplogroup J. This findin
g suggests that one ancient combination of haplogroup J-specific mutat
ions increases both the penetrance of the two primary mutations 11778
and 14484 and the risk of disease expression.